Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets.
In vitro platelet proaggregating effect of unfractionated heparin (H) and OP/LMWH were studied with human platelets. OP/LMWH produced a significant less potentiation of ADP and PAF induced aggregation and slightly counteracted the antiaggregating effect of PGI2, in comparison with H. The proaggregating effect of both heparins was neutralized by equal contemporaneous amount of protamine sulfate.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D001779:Blood Coagulation Factors / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D011464:Epoprostenol / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008970:Molecular Weight; D010972:Platelet Activating Factor; D010974:Platelet Aggregation / Q000187:drug effects*
D001779:Blood Coagulation Factors; D010972:Platelet Activating Factor; D000244:Adenosine Diphosphate; D006493:Heparin; D011464:Epoprostenol